<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541797</url>
  </required_header>
  <id_info>
    <org_study_id>UW 19-010</org_study_id>
    <nct_id>NCT04541797</nct_id>
  </id_info>
  <brief_title>Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics With Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)</brief_title>
  <acronym>CATCH-EM</acronym>
  <official_title>Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics With Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study design is a double blinded randomised control trial study that aims to conduct a&#xD;
      randomised controlled trial of empagliflozin and determine if empagliflozin will improve&#xD;
      myocardial blood flow in asymptomatic high risk type 2 diabetic patients. Also, to determine&#xD;
      a cut-off using maximum upslope ratio and myocardial perfusion reserve index in which&#xD;
      patients would demonstrate an improvement in myocardial blood flow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is unknown whether empagliflozin will improve myocardial blood flow and resolve myocardial&#xD;
      ischaemia caused by microvascular coronary artery disease in asymptomatic patients with type&#xD;
      2 diabetes.This study proposes to perform a randomised controlled trial to compare optimised&#xD;
      medical therapy against empagliflozin in addition to optimised medical therapy to improve&#xD;
      myocardial blood flow as measured by stress CMR. This trial would provide evidence if 10mg of&#xD;
      empagliflozin given for 6 months could be an indicated treatment in asymptomatic high risk&#xD;
      type 2 diabetic patients using stress CMR. The duration of 6 months is slightly longer than&#xD;
      the mouse study (ie. 5 months) which showed an improvement in myocardial blood flow but not&#xD;
      too long that the risk of increased patient withdrawal from the study will occur.&#xD;
&#xD;
      All patients will undergo coronary CT angiography in order to assess degree of coronary&#xD;
      artery narrowing non-invasively before allocation to the control or intervention group.&#xD;
      Patients will also undergo coronary CT angiography at the end of the study after 6 months of&#xD;
      placebo or empagliflozin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blinded randomised control trial study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>A stratified block randomisation process will be used. Two blocks will be created for randomisation which are 1) Positive stress CMR patients who did not have significant coronary artery disease; 2) Negative stress CMR patients. This will ensure equal spread of these two groups of patients into the control and intervention arm.&#xD;
Patients will be randomised into control and intervention arms. Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).&#xD;
Intervention group: Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in myocardial blood flow as measured by stress CMR (ie. maximum upslope ratio and myocardial perfusion reserve index) between patients receiving empagliflozin and patients not receiving empagliflozin.</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cut-off value for maximum upslope ratio to predict ≥10% increase in myocardial blood flow as result of empagliflozin.</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cut-off value for myocardial perfusion index to predict ≥10% increase in myocardial blood flow as result of empagliflozin.</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in myocardial blood flow (MBF) in the intervention arm patients comparing patients with positive stress CMR to patients with negative stress CMR.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular volumes.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular myocardial mass.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular ejection fraction.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular volumes.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular myocardial mass.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of empagliflozin therapy complication (eg. Urinary tract infection, acute renal failure).</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression in patient symptoms diagnoses.</measure>
    <time_frame>36 months</time_frame>
    <description>The Seattle Angina Questionnaire (SAQ) will be administered at time of baseline CMR and at follow-up CMR in order to determine if there is an improvement in patient symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in exercise tolerance through performing a cardiopulmonary exercise test.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Microvascular Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>Intervention group: Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Empagliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Stress Cardiac Magnetic Resonance</intervention_name>
    <description>Imaging: All patients will have stress CMR examinations at recruitment.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Stress CMR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Onset of type 2 diabetes at ≥30yrs old with no history of ketoacidosis&#xD;
&#xD;
          -  40-90yrs old&#xD;
&#xD;
          -  Any 2 risk factors which include:&#xD;
&#xD;
             i) Smoking (ie. current or ex-smokers) ii) Dyslipidaemia (defined as low density&#xD;
             lipoprotein ≥2.6mmol/L, triglyceride &gt;1.7mmol/L or decreased high density lipoprotein&#xD;
             cholesterol &lt;1.04mmol/L [man] or &lt;1.29mmol/L [woman] or on lipid-lowering agent)(17,&#xD;
             18) iii) Hypertension (ie. systolic blood pressure &gt;140mmHg or diastolic blood&#xD;
             pressure &gt;90mmHg or patients treated for hypertension) iv) Obesity (using definition&#xD;
             adapted for chinese ethnicity, body mass index &gt;25kg/m2)(19) v) Family history of&#xD;
             premature heart disease (defined as 1st degree relative [ie. parent or sibling] with&#xD;
             development of atherosclerotic cardiovascular disease or cardiovascular related death&#xD;
             &lt;55 years of age in male and &lt;65 years of age in female)&#xD;
&#xD;
          -  HbA1c ≥ 6.5% and &lt;10.0%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Angina pectoris or chest discomfort&#xD;
&#xD;
          -  Prior coronary artery bypass grafts&#xD;
&#xD;
          -  Coronary artery stenting within 6 months of study enrolment&#xD;
&#xD;
          -  Previous myocardial infarct&#xD;
&#xD;
          -  Any contraindication for stress CMR testing&#xD;
&#xD;
          -  Renal impairment with eGFR &lt;45ml/min/1.73m2&#xD;
&#xD;
          -  Limited life expectancy &lt;5 years, for example due to pulmonary disease, cancer or&#xD;
             significant hepatic failure&#xD;
&#xD;
          -  Contraindication to dual antiplatelet therapy&#xD;
&#xD;
          -  Contraindication to empagliflozin or other SGLT2 inhibitors&#xD;
&#xD;
          -  Unable to take empagliflozin&#xD;
&#xD;
          -  Patients currently on empagliflozin or given empagliflozin in the last 6 months&#xD;
&#xD;
          -  Planned need for concomitant cardiac surgery or coronary intervention&#xD;
&#xD;
          -  Refusal or inability to sign an informed consent.&#xD;
&#xD;
          -  Potential for non-compliance towards the requirements in the trial protocol&#xD;
             (especially the medical treatment) or follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming-Yen NG, BMBS</last_name>
    <phone>(+852) 22552524</phone>
    <email>myng2@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Yen NG, BMBS</last_name>
      <phone>(+852) 22554524</phone>
      <email>myng2@hku.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

